Global Hip Osteoarthritis Pain Medicine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • Hip Osteoarthritis Pain Medicine market report explains the definition, types, applications, major countries, and major players of the Hip Osteoarthritis Pain Medicine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Sanofi

    • GlaxoSmithKline

    • Abiogen Pharma

    • Johnson & Johnson

    • Tide Pharmaceutical

    • Horizon Pharma

    • Astellas Pharma

    • Iroko Pharmaceuticals

    • TEVA

    • Novartis

    • Mylan

    • Pfizer

    • Abbott

    • Bayer

    • Almatica Pharma

    • Hengrui Pharmaceutical

    • Daiichi Sankyo

    • Eli Lilly

    By Type:

    • Oral

    • Injection

    • External

    By End-User:

    • Medical Care

    • Personal Care

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Hip Osteoarthritis Pain Medicine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Hip Osteoarthritis Pain Medicine Outlook to 2028- Original Forecasts

    • 2.2 Hip Osteoarthritis Pain Medicine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Hip Osteoarthritis Pain Medicine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Hip Osteoarthritis Pain Medicine Market- Recent Developments

    • 6.1 Hip Osteoarthritis Pain Medicine Market News and Developments

    • 6.2 Hip Osteoarthritis Pain Medicine Market Deals Landscape

    7 Hip Osteoarthritis Pain Medicine Raw Materials and Cost Structure Analysis

    • 7.1 Hip Osteoarthritis Pain Medicine Key Raw Materials

    • 7.2 Hip Osteoarthritis Pain Medicine Price Trend of Key Raw Materials

    • 7.3 Hip Osteoarthritis Pain Medicine Key Suppliers of Raw Materials

    • 7.4 Hip Osteoarthritis Pain Medicine Market Concentration Rate of Raw Materials

    • 7.5 Hip Osteoarthritis Pain Medicine Cost Structure Analysis

      • 7.5.1 Hip Osteoarthritis Pain Medicine Raw Materials Analysis

      • 7.5.2 Hip Osteoarthritis Pain Medicine Labor Cost Analysis

      • 7.5.3 Hip Osteoarthritis Pain Medicine Manufacturing Expenses Analysis

    8 Global Hip Osteoarthritis Pain Medicine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Hip Osteoarthritis Pain Medicine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Hip Osteoarthritis Pain Medicine Export by Region (Top 10 Countries) (2017-2028)

    9 Global Hip Osteoarthritis Pain Medicine Market Outlook by Types and Applications to 2022

    • 9.1 Global Hip Osteoarthritis Pain Medicine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Injection Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global External Consumption and Growth Rate (2017-2022)

    • 9.2 Global Hip Osteoarthritis Pain Medicine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Medical Care Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Personal Care Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Hip Osteoarthritis Pain Medicine Market Analysis and Outlook till 2022

    • 10.1 Global Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.2.2 Canada Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.2.3 Mexico Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.2 UK Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.3 Spain Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.4 Belgium Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.5 France Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.6 Italy Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.7 Denmark Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.8 Finland Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.9 Norway Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.10 Sweden Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.11 Poland Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.12 Russia Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.3.13 Turkey Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.2 Japan Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.3 India Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.4 South Korea Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.5 Pakistan Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.6 Bangladesh Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.7 Indonesia Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.8 Thailand Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.9 Singapore Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.10 Malaysia Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.11 Philippines Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.4.12 Vietnam Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.2 Colombia Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.3 Chile Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.4 Argentina Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.5 Venezuela Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.6 Peru Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.7 Puerto Rico Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.5.8 Ecuador Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.6.2 Kuwait Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.6.3 Oman Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.6.4 Qatar Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.7.2 South Africa Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.7.3 Egypt Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.7.4 Algeria Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

      • 10.8.2 New Zealand Hip Osteoarthritis Pain Medicine Consumption (2017-2022)

    11 Global Hip Osteoarthritis Pain Medicine Competitive Analysis

    • 11.1 Sanofi

      • 11.1.1 Sanofi Company Details

      • 11.1.2 Sanofi Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Sanofi Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.1.4 Sanofi Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 GlaxoSmithKline

      • 11.2.1 GlaxoSmithKline Company Details

      • 11.2.2 GlaxoSmithKline Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 GlaxoSmithKline Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.2.4 GlaxoSmithKline Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Abiogen Pharma

      • 11.3.1 Abiogen Pharma Company Details

      • 11.3.2 Abiogen Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Abiogen Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.3.4 Abiogen Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Johnson & Johnson

      • 11.4.1 Johnson & Johnson Company Details

      • 11.4.2 Johnson & Johnson Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Johnson & Johnson Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.4.4 Johnson & Johnson Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Tide Pharmaceutical

      • 11.5.1 Tide Pharmaceutical Company Details

      • 11.5.2 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.5.4 Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Horizon Pharma

      • 11.6.1 Horizon Pharma Company Details

      • 11.6.2 Horizon Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Horizon Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.6.4 Horizon Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Astellas Pharma

      • 11.7.1 Astellas Pharma Company Details

      • 11.7.2 Astellas Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Astellas Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.7.4 Astellas Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Iroko Pharmaceuticals

      • 11.8.1 Iroko Pharmaceuticals Company Details

      • 11.8.2 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.8.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 TEVA

      • 11.9.1 TEVA Company Details

      • 11.9.2 TEVA Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 TEVA Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.9.4 TEVA Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Novartis

      • 11.10.1 Novartis Company Details

      • 11.10.2 Novartis Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Novartis Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.10.4 Novartis Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Mylan

      • 11.11.1 Mylan Company Details

      • 11.11.2 Mylan Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Mylan Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.11.4 Mylan Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Pfizer

      • 11.12.1 Pfizer Company Details

      • 11.12.2 Pfizer Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Pfizer Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.12.4 Pfizer Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    • 11.13 Abbott

      • 11.13.1 Abbott Company Details

      • 11.13.2 Abbott Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.13.3 Abbott Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.13.4 Abbott Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.13.5 Recent Research and Development Strategies

    • 11.14 Bayer

      • 11.14.1 Bayer Company Details

      • 11.14.2 Bayer Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.14.3 Bayer Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.14.4 Bayer Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.14.5 Recent Research and Development Strategies

    • 11.15 Almatica Pharma

      • 11.15.1 Almatica Pharma Company Details

      • 11.15.2 Almatica Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.15.3 Almatica Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.15.4 Almatica Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.15.5 Recent Research and Development Strategies

    • 11.16 Hengrui Pharmaceutical

      • 11.16.1 Hengrui Pharmaceutical Company Details

      • 11.16.2 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.16.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.16.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.16.5 Recent Research and Development Strategies

    • 11.17 Daiichi Sankyo

      • 11.17.1 Daiichi Sankyo Company Details

      • 11.17.2 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.17.3 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.17.4 Daiichi Sankyo Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.17.5 Recent Research and Development Strategies

    • 11.18 Eli Lilly

      • 11.18.1 Eli Lilly Company Details

      • 11.18.2 Eli Lilly Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.18.3 Eli Lilly Hip Osteoarthritis Pain Medicine Main Business and Markets Served

      • 11.18.4 Eli Lilly Hip Osteoarthritis Pain Medicine Product Portfolio

      • 11.18.5 Recent Research and Development Strategies

    12 Global Hip Osteoarthritis Pain Medicine Market Outlook by Types and Applications to 2028

    • 12.1 Global Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Injection Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global External Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Medical Care Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Personal Care Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Hip Osteoarthritis Pain Medicine Market Analysis and Outlook to 2028

    • 13.1 Global Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.2.2 Canada Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.2 UK Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.3 Spain Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.5 France Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.6 Italy Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.8 Finland Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.9 Norway Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.11 Poland Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.12 Russia Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.2 Japan Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.3 India Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.3 Chile Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.6 Peru Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.6.3 Oman Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Hip Osteoarthritis Pain Medicine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Hip Osteoarthritis Pain Medicine

    • Figure of Hip Osteoarthritis Pain Medicine Picture

    • Table Global Hip Osteoarthritis Pain Medicine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Hip Osteoarthritis Pain Medicine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Oral Consumption and Growth Rate (2017-2022)

    • Figure Global Injection Consumption and Growth Rate (2017-2022)

    • Figure Global External Consumption and Growth Rate (2017-2022)

    • Figure Global Medical Care Consumption and Growth Rate (2017-2022)

    • Figure Global Personal Care Consumption and Growth Rate (2017-2022)

    • Figure Global Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Table North America Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure United States Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Canada Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Mexico Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table Europe Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure Germany Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure UK Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Spain Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Belgium Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure France Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Italy Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Denmark Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Finland Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Norway Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Sweden Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Poland Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Russia Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Turkey Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table APAC Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure China Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Japan Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure India Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Thailand Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Singapore Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Philippines Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table South America Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure Brazil Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Colombia Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Chile Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Argentina Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Peru Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table GCC Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure Bahrain Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Oman Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Qatar Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table Africa Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure Nigeria Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Africa Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Egypt Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure Algeria Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table Oceania Hip Osteoarthritis Pain Medicine Consumption by Country (2017-2022)

    • Figure Australia Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Hip Osteoarthritis Pain Medicine Consumption and Growth Rate (2017-2022)

    • Table Sanofi Company Details

    • Table Sanofi Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Sanofi Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table GlaxoSmithKline Company Details

    • Table GlaxoSmithKline Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table GlaxoSmithKline Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Abiogen Pharma Company Details

    • Table Abiogen Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abiogen Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Abiogen Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Johnson & Johnson Company Details

    • Table Johnson & Johnson Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Johnson & Johnson Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Tide Pharmaceutical Company Details

    • Table Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Tide Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Horizon Pharma Company Details

    • Table Horizon Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Horizon Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Horizon Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Astellas Pharma Company Details

    • Table Astellas Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Astellas Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Iroko Pharmaceuticals Company Details

    • Table Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Iroko Pharmaceuticals Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table TEVA Company Details

    • Table TEVA Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table TEVA Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table TEVA Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Novartis Company Details

    • Table Novartis Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Novartis Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Mylan Company Details

    • Table Mylan Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Mylan Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Pfizer Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Abbott Company Details

    • Table Abbott Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Abbott Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Bayer Company Details

    • Table Bayer Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Bayer Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Almatica Pharma Company Details

    • Table Almatica Pharma Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Almatica Pharma Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Almatica Pharma Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Hengrui Pharmaceutical Company Details

    • Table Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Hengrui Pharmaceutical Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Daiichi Sankyo Company Details

    • Table Daiichi Sankyo Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Daiichi Sankyo Hip Osteoarthritis Pain Medicine Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Hip Osteoarthritis Pain Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Hip Osteoarthritis Pain Medicine Main Business and Markets Served

    • Table Eli Lilly Hip Osteoarthritis Pain Medicine Product Portfolio

    • Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Injection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global External Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Medical Care Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Personal Care Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Table North America Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure United States Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure Germany Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure China Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure Brazil Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Hip Osteoarthritis Pain Medicine Consumption Forecast by Country (2022-2028)

    • Figure Australia Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Hip Osteoarthritis Pain Medicine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.